Edgewise Therapeutics (NASDAQ: EWTX) holder Novo Holdings at 4.98%

Rhea-AI Filing Summary

Novo Holdings A/S filed Amendment No. 6 to its Schedule 13D on Edgewise Therapeutics, Inc., reporting that its ownership has been diluted below five percent of the company’s common stock.

Novo Holdings beneficially owns 5,350,000 shares of common stock, representing approximately 4.98% of Edgewise’s outstanding shares, based on 107,532,173 shares outstanding as of April 9, 2026. The filing states this change results from dilution rather than any purchase or sale of shares, and confirms no transactions in the stock by Novo Holdings or related parties within the past 60 days.

Key Figures

Beneficial ownership shares: 5,350,000 shares Ownership percentage: 4.98% Shares outstanding: 107,532,173 shares +1 more

4 metrics

Beneficial ownership shares 5,350,000 shares Novo Holdings A/S beneficially owned Edgewise common stock

Ownership percentage 4.98% Percent of Edgewise outstanding common stock held by Novo Holdings

Shares outstanding 107,532,173 shares Edgewise common stock outstanding as of April 9, 2026

Rounded ownership on cover 4.9% Row 13 percentage rounded down due to EDGAR field limits

Key Terms

beneficially owns, Schedule 13D, definitive proxy statement, sole power to vote and dispose, +1 more

5 terms

beneficially owns financial

"Novo Holdings A/S beneficially owns 5,350,000 shares of common stock"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

Schedule 13D regulatory

"This Amendment No. 6 ... amends and supplements the statement on originally filed ..."

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

definitive proxy statement regulatory

"based upon 107,532,173 shares of common stock outstanding ... as reported in the Issuer's definitive proxy statement"

A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.

sole power to vote and dispose financial

"Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares"

beneficial owner of more than five percent regulatory

"The Reporting Person ceased to be the beneficial owner of more than five percent of the Common Stock"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/27/2026 - 04:49 PM Learn about SEC filing dates

FAQ

What ownership stake does Novo Holdings A/S report in Edgewise Therapeutics (EWTX)?

Novo Holdings A/S reports beneficial ownership of 5,350,000 shares of Edgewise Therapeutics common stock, representing approximately 4.98% of the outstanding shares. This percentage is based on 107,532,173 shares outstanding as of April 9, 2026, per Edgewise’s definitive proxy statement.

Why did Novo Holdings file Amendment No. 6 to its Schedule 13D on Edgewise Therapeutics (EWTX)?

Amendment No. 6 was filed to report the dilution of Novo Holdings’ beneficial ownership in Edgewise Therapeutics below five percent. The filing clarifies that this change is not the result of any acquisition or disposition of Edgewise securities by Novo Holdings or related parties.

Did Novo Holdings trade Edgewise Therapeutics (EWTX) shares in the last 60 days?

The filing states that Novo Holdings A/S, the Novo Nordisk Foundation, and all persons listed on the updated Schedule I have not effected any transactions in Edgewise Therapeutics common stock within the past 60 days, indicating the ownership change stems from dilution, not trading activity.

When did Novo Holdings cease to be a 5% beneficial owner of Edgewise Therapeutics (EWTX)?

Novo Holdings reports that it ceased to be the beneficial owner of more than five percent of Edgewise Therapeutics common stock on April 23, 2026. After this date, its reported ownership percentage stood at approximately 4.98% of the outstanding common shares.

Who controls voting and disposition of Novo Holdings’ Edgewise Therapeutics (EWTX) shares?

Novo Holdings A/S, a Danish corporation wholly owned by the Novo Nordisk Foundation, has the sole power to vote and dispose of the Edgewise shares. Neither the Foundation nor any person on the updated Schedule I can direct the vote or disposition of these shares.

What share count did Novo Holdings use to calculate its 4.98% stake in Edgewise Therapeutics (EWTX)?

The reported 4.98% ownership is based on 107,532,173 shares of Edgewise common stock outstanding as of April 9, 2026, as disclosed in Edgewise Therapeutics’ definitive proxy statement filed with the SEC on April 23, 2026.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 6)

Edgewise Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

28036F105

(CUSIP Number)

Barbara Fiorini
Novo Holdings A/S, Tuborg Havnevej 19
Hellerup, G7, DK-2900
45 3527 6592

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

04/23/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 28036F105

1

Name of reporting person

Novo Holdings A/S

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DENMARK

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 5,350,000.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 5,350,000.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

5,350,000.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.9 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001 per share
(b)	Name of Issuer: Edgewise Therapeutics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 1715 38th St., Boulder, COLORADO , 80301.
Item 1 Comment: This Amendment No. 6 (this "Amendment No. 6" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on March 31, 2021, and amended on September 16, 2022, September 30, 2022, June 28, 2023, January 25, 2024 and September 23, 2024 (as amended, the "Statement") by the Reporting Person. This Amendment No. 6 is being filed to report the dilution of the Reporting Person's beneficial ownership in the Issuer's common stock and not as a result of any acquisition or disposition of securities by the Reporting Person. Unless otherwise defined herein, capitalized terms used in this Amendment No. 6 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.
Item 5.	Interest in Securities of the Issuer
(a)	Novo Holdings A/S beneficially owns 5,350,000 shares of common stock representing approximately 4.98% of the Issuer's outstanding shares of common stock, based upon 107,532,173 shares of common stock outstanding as of April 9, 2026, as reported in the Issuer's definitive proxy statement, filed with the SEC on April 23, 2026. Due to field limitations of the EDGAR filing system, the percentage listed in Row 13 of the Reporting Person's cover page has been rounded down to 4.9%.
(b)	Novo Holdings A/S is a Danish corporation wholly owned by the Novo Nordisk Foundation. Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on the updated Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares.
(c)	Novo Holdings A/S has not effected any transactions in the Issuer's common stock within the past 60 days and neither the Foundation nor any person listed on the updated Schedule I has effected any transactions in the Issuer's common stock within the past 60 days.
(d)	Novo Holdings A/S does not know of any other person having the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Novo Shares.
(e)	The Reporting Person ceased to be the beneficial owner of more than five percent of the Common Stock on April 23, 2026.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 99.1 Schedule I

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Novo Holdings A/S

Signature:	/s/ Barbara Fiorini
Name/Title:	By Barbara Fiorini, General Counsel, Finance & Operations
Date:	04/27/2026